GSK· @GSK · X·· 9 小时前精选AI 评分58
AI 导读
GSK宣布,日本厚生劳动省(MHLW)已为其治疗胃肠道间质瘤(GIST)的在研药物授予孤儿药认定。GSK称这是重要进展,并重申对该罕见癌症患者的承诺。
推荐理由
日本厚生劳动省对GSK在研GIST药物授予孤儿药认定,读者可据此了解该罕见肿瘤在研疗法的监管进展。
正文
#News for #Investors and #Media: Today we announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation for our investigational medicine for the treatment of gastrointestinal stromal tumour (GIST).
This marks a significant advancement and reinforces our commitment to people living with this rare cancer.
Learn more: https://gsk.to/4zrzdjN
来源:GSK · x.com